Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone water vs powder formulations in pediatric acute non-lymphocytic leukemia (non-M3)
ChiCTR2200063394Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of mitoxantrone in acute myeloid leukemia (AML) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Heart failure, Heart enlargement and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
mitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200063394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063394.